Silver Book Fact

Cost of pneumonia vaccine

Addition of PCV13 (13-valent pneumococcal conjugate vaccine) to previously recommended pneumococcal polysaccharide vaccine for immunocompromised adults cost $70,937 per quality adjusted life year compared to no vaccine.

Smith K, Nowalk M, Raymund M, Zimmerman R. Cost-Effectiveness of Pneumococcal Conjugate Vaccination in Immunocompromised Adults. Vaccine. 2013; 31(37): 3950-6. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3742552/

Reference

Title
Cost-Effectiveness of Pneumococcal Conjugate Vaccination in Immunocompromised Adults
Publication
Vaccine
Publication Date
2013
Authors
Smith K, Nowalk M, Raymund M, Zimmerman R
Volume & Issue
Volume 31, Issue 37
Pages
3950-6
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • Effectiveness of pneumonia vaccine
    PPSV23 (pneumococcal polysaccharide vaccine) protects against 23 types of pneumococcal bacteria and is 60% to 80% effective in preventing pneumococcal bacteremia in adults over the age of 65 who are…  
  • Influenza vaccine use reduces antibiotic use
    Use of LAIV (live attenuated influenza virus) in healthy adults ages 18 to 65 reduced antibiotic use by 43% to 47%.  
  • Measles vaccines reduced cases from 6 million to 1 million per year
    Vaccination for measles reduced the number of worldwide deaths from 6 million in 1974 to less than 1 million per year.  
  • Vaccines save lives and money
    Between 2001 and 2010, vaccine use prevented an estimated 170,000 severe pneumococcal infections and 10,000 deaths, and saved an estimated $310 million in direct medical costs each year.  
  • Vaccines in development 2013
    Vaccines in development for 2013